HKTDC International Sourcing Show Opens on 17 March, Online-and-Offline Fair Helps Businesses Capture New Opportunities
17.3.2021 04:44:00 EET | Business Wire | Press release
The Hong Kong Trade Development Council (HKTDC) is debuting the HKTDC International Sourcing Show, a trade exhibition held in both online and physical formats, to help businesses adjust to the new sourcing model. The online section of the show begins on 17 March and will enable buyers and suppliers to engage through business matching and video conferencing tools. Once the pandemic situation eases, businesses can join the physical show at the Hong Kong Convention and Exhibition Centre from 26 to 29 July to explore further opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316006131/en/
In response to the pandemic’s impact on trade exhibitions globally, the HKTDC is debuting the HKTDC International Sourcing Show that will be held in both online and physical formats. The online section of the show begins on 17 March. At an online media briefing held on 16 March to introduce the event, HKTDC Deputy Executive Director Benjamin Chau gave an overview of the show’s highlights (Photo: Business Wire)
With the theme “Your Source of Inspiration”, the show will highlight a broad range of quality lifestyle products and solutions:
- Smart Home: Featuring an extensive selection of houseware, home textiles and furnishings
- Smart Play: Showcasing a range of baby products and toys and games
- Smart Style: Highlighting fashion products, gifts and premiums as well as printing and packaging solutions
- Smart Tech: Displaying electronics, lighting and medical and healthcare products employing the latest technologies.
More than 1,400 companies from 20 countries and regions will exhibit at the show. Some exhibitors have opted to use 3D virtual booths to promote their brands and products in more eye-catching ways. The HKTDC has also launched a product video production service to enable resource-strapped SMEs to design and produce videos to help them catch the attention of buyers.
Over 60 industry luminaries are invited to share their insights in 17 webinars. Highlighted webinars include “International Sourcing Outlook”, “Survive and Thrive: Leveraging End-to-end E-commerce Solutions” and “Utilising Licensing to Expand Your Business”.
Highlighted speakers include Devin Dai, Director of Category Management at Alibaba.com, Shinya Hisanaga, Director of Buying and Logistics at AEON Stores (Hong Kong), Flavien Serra, Founder of DTL Sourcing, Fione Tan, Co-founder of 28Mall.com, and Benson Ng, Hong Kong Business Consulting Leader at EY.
Furthermore, the show will continue to feature Click2Match, an AI-powered online business matching platform. Buyers and suppliers can use the tool to enjoy functions such as a meeting planner, video meetings, live chat and e-business card exchange, helping them to overcome barriers under the pandemic and build business connections around the world.
Don’t miss this chance to get inspired. Register now to source, learn, connect and explore.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316006131/en/
Contact information
Hong Kong Trade Development Council
Cathy Li cathy.hm.li@hktdc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom